Journal Article DKFZ-2017-00300

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2014
Taylor & Francis Group Abingdon

Amyloid 21(1), 9 - 17 () [10.3109/13506129.2013.854766]
 GO

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: Chromosomal aberrations of plasma cells are well established pathogenetic and prognostic factors in multiple myeloma, but their prognostic implication in systemic light chain (AL) amyloidosis is unclear. Therefore, the aim of this study was to identify prognostic cytogenetic risk factors by interphase FISH in a series of 103 consecutive AL amyloidosis patients treated uniformly with melphalan/dexamethasone as first-line therapy. Detection of gain of 1q21 was predictive for a poor overall survival (OS) (median 12.5 versus 38.2 months, p = 0.002). Hematologic event free survival (hem EFS) for gain of 1q21 was 5.0 versus 8.5 months in median (p = 0.08) and haematologic remission rates (≥VGPR) after three cycles were 5% versus 25% (p = 0.06). Most important, in multivariate concordance analyses the adverse prognosis carried by gain of 1q21 was retained as an independent prognostic factor (OS: p = 0.003, average hazard ratio (AHR) = 3.64, hemEFS: p = 0.008, AHR = 2.35), along with the well established Mayo cardiac staging. Patients with t(11;14) had a longer median OS with 38.2 months versus 17.5 months, though no statistical significance was reached. Deletion 13q14 and hyperdiploidy turned out to be prognostically neutral. In conclusion, we have identified gain of 1q21 as an independent adverse prognostic factor in AL amyloidosis patients treated with standard chemotherapy.

Keyword(s): Immunoglobulin Light Chains ; Dexamethasone ; Melphalan

Classification:

Contributing Institute(s):
  1. KKE Molekulare Hämatologie/Onkologie (G330)
  2. Biostatistik (C060)
Research Program(s):
  1. 317 - Translational cancer research (POF3-317) (POF3-317)

Appears in the scientific report 2014
Database coverage:
Medline ; BIOSIS Previews ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2017-03-03, last modified 2024-02-28



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)